Page 5 - Param Desai News Today : Breaking News, Live Updates & Top Stories | Vimarsana

pharma stocks to buy: Param Desai s 4 top picks in largecap and midcap pharma

“We believe that Ciplas Pithampur facility was inspected in February and post that, they got an OAI in August and post that, it has escalated to a warning letter. We believe that it is unlikely that this will escalate further to import alerts, though this may take some time to resolve.”

Uttar pradeshParam desaiSun pharmaPrabhudas lilladherIndian school of businessSenior research analystOffering collegeTorrent pharmaLeadership excellenceMarketing officerProduct officerMight also likePharma stocks to buyParam desai prabhudas lilladherJb chemicalsExpert view

Stock Market Live Updates: Sensex, Nifty trade flat; auto stocks in focus

Stock Market Live Updates: Sensex, Nifty trade flat; auto stocks in focus
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

India generalCzech republicMadhya pradeshUnited statesHong kongSaudi arabiaSoult ukpyolsiSouth koreaUnited kingdomBhaskar raoSriram iyerPrashanth tapseSun pharmaParam desaiShrikant chouhanAnand james

US sales momentum, margin gains to support pharma major Cipla s stock

A strong performance in the July-September quarter of 2023-24 (Q2FY24), an upward revision in the margin guidance and sustained momentum in US sales has helped the stock of pharmaceutical major Cipla gain about 2 per cent over the last two trading sessions. The brokerages have upgraded the earnings estimates for this financial year (FY24) by 6-9 per cent to factor in the improved margin guidance and sales in the US market. Led by the US market, which rose by 31 per cent, the company posted a 16 per cent growth in revenues.

Param desaiKushal shahMotilal oswal researchPrabhudas lilladher researchLilladher researchBusiness newsUsiness news indiaNdia business newsNdian economy newsNdian financial news

Strong profit growth keeps brokerages positive on Torrent

Even as the broader markets were under pressure, the stock of Torrent Pharmaceuticals was down 1.05 per cent on October 26. This was on expectation that steady sales growth momentum in core markets such as India and Brazil and recovery in the US market coupled with margin expansion will drive strong earnings growth over the next couple of years. Brokerages are working with the net profit growth of 28-34 per cent annually over the FY23-25 period.

Andhra pradeshUnited statesTamil naduKushal shahParam desaiPrabhudas lilladher researchNirmal bang researchWhile motilal oswal researchTorrent pharmaceuticalsLatin americaBang researchMotilal oswal researchBusiness newsUsiness news indiaNdia business newsNdian economy news

Aurobindo Pharma: Strong prospects offset by valuation concerns

Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those gains coming in the last three months. The stock is riding on multiple triggers given its investments in the production-linked incentive or PLI scheme, biosimilars, injectables and vaccines, which should drive revenues and profits over the medium term. Better than expected performance after the June quarter results led to a revision of earnings estimates for FY24 and FY25.

Aurobindo pharmaAashita jainKunal randeriaParam desaiNuvama researchPrabhudas lilladher researchMacquarie researchLilladher researchBusiness newsUsiness news indiaNdia business newsNdian economy newsNdian financial news